Skip to main content

4 Result(s)

within H.-J. Hertfelder Remove this filter English Remove this filter

and

  1. Article

    Open Access

    Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness

    Omalizumab is an effective therapeutic humanized murine IgE antibody in many cases of primary systemic mast cell activation disease (MCAD). The present study should enable the clinician to recognize when treat...

    G. J. Molderings, F. L. Dumoulin, J. Homann… in Naunyn-Schmiedeberg's Archives of Pharmaco… (2020)

    Download PDF (374 KB) View Article

  2. No Access

    Article

    The coagulation system of extremely preterm infants: influence of perinatal risk factors on coagulation

    Little is known about the influence of preterm delivery and perinatal risk factors on development and expression of the coagulation system in extremely preterm infants. The objective of this study was to deter...

    C Poralla, C Traut, H-J Hertfelder, J Oldenburg, P Bartmann… in Journal of Perinatology (2012)

  3. No Access

    Chapter and Conference Paper

    Missense Mutations at ALA-10 in the Factor IX Propeptide: A Novel Mechanism for Severe Bleeding During Oral Anticoagulant Therapy

    Bleeding complications represent the most common and unwanted side effect of oral anticoagulant therapy. We present a novel mechanism for bleeding during coumarin therapy, attributed to newly described missens...

    J. Oldenburg, E. M. Quenzel, U. Harbrecht… in 27. Hämophilie-Symposion Hamburg 1996 (1998)

  4. No Access

    Article

    Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy

     Two male patients with severe and recurrent bleeding episodes under phenprocoumon therapy are reported. Both patients exhibited a strong decrease of their factor IX activities below 1% of normal, whereas the ...

    E.-M. Quenzel, H.-J. Hertfelder, J. Oldenburg in Annals of Hematology (1997)